Naloxone prescribing, dispensing, distribution, and administration
Customize your policy alerts
Sign up for all Idaho Department of Health and Welfare policy alerts
Know when Idaho Department of Health and Welfare releases new policies or updates existing guidance.
Monitor payer policy activity
Guidance for healthcare and community-based organizations in Idaho on prescribing, dispensing, distributing, and administering naloxone, including legal protections, reporting, and how organizations can obtain naloxone from DHW or manufacturers.
No material clinical or coverage changes in this revision.
Permitted Uses and Scope
Permitted uses and obligations
Permitted actions under Idaho statute and DHW guidance
Idaho Statute 54-1733B subsection (1); DHW FAQ
DHW FAQ referencing Idaho Statute 54-1733
Idaho Statute 54-1733B subsection (2); DHW FAQ
DHW FAQ (distribution allowed; standing order not required; manufacturer supply not considered dispensing)
DHW FAQ: not considered dispensing if received directly from manufacturer
Idaho Statute 54-1733B subsection (3)
DHW FAQ PDMP reporting guidance
If an organization receives naloxone directly from a manufacturer, that transfer is not considered dispensing under Idaho guidance. Dispensing is defined as the preparation and delivery of naloxone in accordance with a lawful prescription order; transfers directly from a manufacturer to an organization fall outside that definition.
Provider Requirements, Billing, and Reporting
Prior authorization and coverage
Coverage and cost vary by insurer; prescription naloxone usually requires a copay for commercial plans. Medicaid beneficiaries receive naloxone at no cost at the pharmacy (no copay); family, friends, or the individual may request naloxone with a Medicaid number and patient name. Providers dispensing or prescribing may consider registering for an NPI to assist with billing.
Step therapy requirements
There are no step therapy requirements described in this guidance for naloxone.
Documentation and billing note
When dispensing naloxone to an individual or entity, document the patient/recipient and, if applicable, the recipient’s Medicaid number and patient name to support dispensing and billing; providers may register for a National Provider Identifier (NPI) to assist with billing.
PDMP reporting requirement
Report naloxone dispensed to an individual or entity to the Idaho PDMP unless the naloxone was requested through the manufacturer or through the Idaho Department of Health and Welfare; failure to report when required may result in noncompliance with PDMP reporting requirements.
- Do not report when naloxone was requested through the manufacturer.
- Do not report when naloxone was requested through the Idaho Department of Health and Welfare.
Clinical Background
Naloxone is an opioid antagonist that rapidly reverses opioid overdose by restoring respiration and reversing opioid effects. It is available in multiple formulations suitable for out-of-hospital use.
Common community and bystander formulations include intranasal (nasal spray) and auto‑injector devices, which are designed for use by laypersons with minimal training. Injectable naloxone (syringe/ampule) exists but generally requires training to administer safely and is less practical for untrained bystanders.
Key Definitions
Appropriate Settings and Formulations
Home and community use formulations
Use nasal spray or auto-injectable naloxone formulations for out-of-hospital, community, and bystander administration; injectable naloxone requires user training and is less typical for home/community use.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.